Improving breast cancer screening in Australia: a public health perspective.


Journal

Public health research & practice
ISSN: 2204-2091
Titre abrégé: Public Health Res Pract
Pays: Australia
ID NLM: 101648133

Informations de publication

Date de publication:
31 Jul 2019
Historique:
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 21 4 2020
Statut: epublish

Résumé

There are currently no single disruptors to breast cancer screening akin to the impact of human papillomavirus testing and vaccination on cervical cancer screening. However, there is a groundswell of interest to review the BreastScreen Australia program to consider more risk-based screening protocols and to establish whether to routinely inform women about their breast density. We propose a framework for a considered, evidence-based review. Population-level effectiveness of breast cancer screening is ultimately measured through its impact on breast cancer mortality, and this has been realised in Australia. Effectiveness can also be measured through treatment intensity, estimated overdiagnosis, false-positive screens and health economics measures. Key levers to improve such population-level outcomes include screening participation, screening test sensitivity and specificity, risk assessment and screening protocols. We propose that the review of the program should fall under an evidence-based, consensus-guided framework comprising four complementary elements: improved evidence on current program performance for population risk subgroups; regularly updated evidence on key levers for change; clinical trials and population simulation modelling working in tandem; and consensus-based decision making about the degree of improvement required to justify change. Informing women about their breast density is feasible and would be valued by some BreastScreen clients to help understand the accuracy of their screening test. However, without agreed protocols for screening women with dense breasts, increases in supplemental screening as observed in other settings would, in Australia, shift screening costs to clients and Medicare. This would reduce equity of access to population screening, and maintaining BreastScreen's usual standard of monitoring and quality management (such as screen-detected and interval cancer diagnoses, and imaging and biopsy rates) would require data linkage between BreastScreen and other services. The proposed framework assesses screening effectiveness in the era of personalised medicine, allows review of multiple factors that may together warrant change, and gives full, evidence-based consideration of the benefits, harms and costs of various approaches to breast cancer screening. To be effective, the framework requires a coordinated approach to generating the evidence required for policy makers, with time to prepare appropriate health services.

Identifiants

pubmed: 31384884
pii: 2921911
doi: 10.17061/phrp2921911
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

CN receives salary funding via the project 'Optimising Early Detection of Breast Cancer in Australia', funded by the Australian Department of Health and led by Cancer Council Australia. She jointly leads the development of the AutoDensity automated breast density measurement tool, through a collaboration between the University of Melbourne and the CSIRO. PB is the Chief Executive Officer of the start-up DetectEd-X, which provides radiology training and research.

Auteurs

Carolyn Nickson (C)

Cancer Research Division, Cancer Council NSW, Sydney, Australia; Melbourne School of Population and Global Health, University of Melbourne, VIC, Australia, cnickson@unimelb.edu.au.

Louiza S Velentzis (LS)

Cancer Research Division, Cancer Council NSW, Sydney, Australia; Melbourne School of Population and Global Health, University of Melbourne, VIC, Australia.

Patrick Brennan (P)

Faculty of Health Sciences, University of Sydney, NSW, Australia.

G Bruce Mann (GB)

Breast Service, The Royal Women's and Royal Melbourne Hospital, VIC, Australia; Department of Surgery, University of Melbourne, VIC, Australia.

Nehmat Houssami (N)

Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH